貨號(hào)：GS40037

Aprutumab is an investigational, fully human monoclonal antibody designed to target the Fibroblast Growth Factor Receptor 2 (FGFR2). It was developed as a potential therapeutic for FGFR2-altered solid tumors, particularly in combination with chemotherapy. Its mechanism involves binding to FGFR2, which is intended to block the binding of fibroblast growth factors (FGFs) and inhibit downstream oncogenic signaling pathways that drive tumor cell proliferation and survival. Clinical development has progressed to Phase II trials, primarily focusing on cancers with specific FGFR2 gene abnormalities.